2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness

By afschroeder • August 5, 2025

Bhimraj A, Falck-Ytter Y, Baden LR, Bedimo R, Cawcutt K, Cheng VC, Chew KW, Chiotos K, Daar ES, Dzierba AL, Glidden DV, Hardy EJ, Johnson S, Kim AY, Li JZ, MacBrayne C, Martin GS, Nadig N, Nakamura MM, Pearson JC, Riley L, Shafer RW, Shoham S, Shumaker AH, Tebas P, Tien PC, Loveless J, Morgan RL, Gandhi RT. 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness. Clin Infect Dis. 2025 Aug 4:ciaf424. doi: 10.1093/cid/ciaf424. Epub ahead of print. PMID: 40757658.

Tags: abatacept, covid-19, Harbor UCLA, Infectious Diseases, infliximab, pemivibart, Publications, vilobelimab

Using a generative co-design framework to adapt an exercise intervention as part of a multimodal intervention for patients’ receiving haemodialysis with or at risk of renal cachexia

Blair C, Slee A, McKeaveney C, Maxwell AP, Awan F, Brown M, Carson M, Comer S, Davenport A, Fogarty D, Fouque D, Gooding O, McKinley[...]

Expanding Electrosurgical Device Awareness in Dermatologic Surgery to Hypoglossal Nerve Stimulators

An MB, Rotunda AM. Expanding Electrosurgical Device Awareness in Dermatologic Surgery to Hypoglossal Nerve Stimulators. Dermatol Surg. 2026 Apr 8. doi: 10.1097/DSS.0000000000005120. Epub ahead of[...]

HLA Associations Differ by Ethnicity and Aquaporin-4 Antibody Status in Patients With Neuromyelitis Optica Spectrum Disorders

Niederschweiberer M, Panagiotaropoulou G, Fernandez-Viña MA, Montero-Martin G, Osoegawa K, Behne M, Franke A, Lieb W, Jarius S, Wildemann B, Schindler P, Otto C, Paul[...]